pCDCAR1 CLEC12A h(BBζ, α/β/γ)(CAR-LC336)
The vector of anti-CLL-1 chimeric antigen receptor (CAR) is based on the FcεRI receptor scaffold and constructed for the engineering of T cells to target human CLL-1. The T cells are genetically modified through transduction with a lentiviral vector expressing an alpha chain comprising a scFv of anti-CLL-1 antibody linked to FcεR1γ-SP and FcεR1γ-TM-IC, a beta chain comprising FcεR1γ-ΔITAM linked to 4-1BB (CD137) signaling domain, a gamma chain comprising FcεR1γ-SP-ΔITAM linked to CD3ζ signaling domain. And the vector product was designed for the treatment of acute lymphoblastic leukemia.
Targeting Cell Type
Acute lymphoblastic leukemia
Discription of Signaling Cassetes
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
C-type lectin domain family 12, member A
CLEC12A; C-type lectin domain family 12; member A; CLL1; MICL; CLL-1; DCAL-2; C-type lectin domain family 12 member A; C-type lectin protein CLL-1; C-type lectin-like molecule-1; dendritic cell-associated lectin 2; myeloid inhibitory C-type lectin-like receptor; anti-CLEC12A
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Anti-CLEC12A (SC02-357) h(CD28/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (M5) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (SC02-378) h(CD28/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (G12) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (1075.7) h(CD28/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (M31) h(CD28/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (M31) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (M26) h(CD28/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (21.26) h(CD28/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CLEC12A (M29) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1